Trials / Approved For Marketing
Approved For MarketingNCT03895528
Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy
A Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid Laminopathy
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eiger BioPharmaceuticals · Industry
- Sex
- All
- Age
- 12 Months
- Healthy volunteers
- —
Summary
This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the HGPS disease process resulting in improved outcomes (Gordon et al, 2018). There are no approved treatments for HGPS and progeroid laminopathies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lonafarnib | Farnesyl transferase inhibitor |
Timeline
- First posted
- 2019-03-29
- Last updated
- 2021-04-15
Source: ClinicalTrials.gov record NCT03895528. Inclusion in this directory is not an endorsement.